Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis

doi:10.3748/wjg.v20.i21.6626

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 21

This Article

(382)

(295)

(0)

(11)

(6722)

(38)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Observational Study

World J Gastroenterol. Jun 7, 2014; 20(21): 6626-6631
Published online Jun 7, 2014. doi: 10.3748/wjg.v20.i21.6626

Table 1 Main clinical and demographic characteristics of the subjects n (%)

Characteristics	Total, n = 115	S0, n = 66	S1, n = 33	S2-S3, n = 16
Sex, females	30 (24.1)	16 (24.2)	10 (30.3)	4 (25.0)
Age, yr (mean ± SD)	43.1 ± 10.5	41.3 ± 11.0	46.8 ± 8.6	43.0 ± 11.1
BMI, kg/m² (mean ± SD)	24.8 ± 4.2	24.0 ± 3.5	25.6 ± 5.2	26.7 ± 3.6
BMI ≥ 25 kg/m²	57 (50.0)	28 (42.4)	18 (56.2)	11 (68.7)
AST, IU/L (IQR)	43 (28-73)	39 (25-59)	52 (31-88)	45 (35-73)
ALT, IU/L (IQR)	63 (38-110)	54 (33-73)	70 (38-142)	98 (63-125)
Alkaline phosphatase, IU/L (mean ± SD)	72.2 ± 25.5	77.1 ± 27.8	65.4 ± 16.9	62.6 ± 24.6
GGT, IU/L (IQR)	48 (26-88)	39 (20-57)	58 (32-133)	73 (40-106)
Total bilirubin, μmol/L (IQR)	0.69 (0.49-0.92)	0.70 (0.46-1.06)	0.64 (0.55-0.92)	0.70 (0.54-0.86)
Platelets count, 10³/mm³ (mean ± SD)	221 ± 78	229 ± 81	204 ± 66	223 ± 90
Prothrombin time, % (mean ± SD)	93.9 ± 12.6	93.4 ± 11.5	94.2 ± 15.0	95.4 ± 12.2
HCV infection	82 (71.3)	44 (66.7)	26 (78.8)	12 (75.0)
HBV infection	28 (24.3)	18 (27.3)	7 (21.2)	3 (18.7)
HCV/HIV infection	5 (4.3)	4 (6.1)	0 (0)	1 (6.2)
Fibrosis score (Metavir)
F0	14 (12.2)	9 (13.6)	5 (15.1)	0 (0)
F1	42 (36.5)	29 (43.9)	7 (21.2)	6 (37.5)
F2	31 (27.0)	17 (25.8)	10 (30.3)	4 (25.0)
F3	18 (15.6)	9 (13.6)	7 (21.2)	2 (12.5)
F4	10 (8.7)	2 (3.0)	4 (12.1)	4 (25.0)
Activity grade (Metavir)
A0	12 (10.4)	8 (12.1)	3 (9.1)	1 (6.2)
A1	66 (57.4)	43 (65.1)	14 (42.4)	9 (52.2)
A2	19 (16.5)	7 (10.6)	9 (27.3)	3 (18.7)
A3	18 (15.6)	8 (12.1)	7 (21.2)	3 (18.7)
LSM, kPa (IQR)	6.7 (5.1-9.1)	6.4 (4.9-8.4)	6.7 (4.8-9.5)	8.0 (5.6-11.1)
CAP, dB/m (mean ± SD)	244.4 ± 49.1	227.1 ± 43.1^a	254.6 ± 38.9^b	297.8 ± 49.4^d

SD values represent mean, and interquartile range (IQR) values represent median.

^aP < 0.05 (S0 vs S1);

^bP < 0.01 (S1 vs S2-S3);

^dP < 0.01 (S0 vs S2-S3). BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; CAP: Controlled attenuation parameter; LSM: Liver stiffness measurement.

Full Size Table

Citation: Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Dal Bello B, Filice G, Filice C. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World J Gastroenterol 2014; 20(21): 6626-6631
URL: https://www.wjgnet.com/1007-9327/full/v20/i21/6626.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i21.6626

Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Dal Bello B, Filice G, Filice C. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World J Gastroenterol 2014; 20(21): 6626-6631 [PMID: 24914387 DOI: 10.3748/wjg.v20.i21.6626]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.